<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Minoxidil (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Minoxidil (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Minoxidil (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12253" href="/d/html/12253.html" rel="external">see "Minoxidil (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16020" href="/d/html/16020.html" rel="external">see "Minoxidil (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8774839"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Minoxidil may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and it can exacerbate angina pectoris. Reserve for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and 2 other antihypertensive agents.</p>
<p style="text-indent:-2em;margin-left:2em;">In experimental animals, minoxidil caused several kinds of myocardial lesions and other adverse cardiac effects.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate use: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Administer under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent, to prevent tachycardia and increased myocardial workload. Usually, it must be given with a diuretic, frequently one acting in the ascending limb of the loop of Henle to prevent serious fluid accumulation. When first administering minoxidil, hospitalize and monitor patients with malignant hypertension and those already receiving guanethidine to avoid too rapid or large orthostatic decreases in blood pressure.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869249"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Loniten</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8774874"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Vasodilator, Direct-Acting</li></ul></div>
<div class="block doa drugH1Div" id="F8774967"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent) (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Before prescribing, consider referral to a clinician with expertise in managing hypertension. Reserve for patients with resistant hypertension who do not respond adequately to an optimized 4-drug regimen, ideally consisting of a thiazide-like diuretic (eg, chlorthalidone) and a mineralocorticoid-receptor antagonist (eg, spironolactone). Use in combination with a beta-blocker to prevent reflex tachycardia. Fluid retention may occur and may require additional diuretic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Brook.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Brook.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 mg once daily, increase dose gradually in intervals of ≥3 days; usual effective dose: 10 to 40 mg/day in 1 to 3 divided doses; maximum dose: 100 mg/day in 1 to 3 divided doses. During therapy, if supine diastolic pressure is reduced &lt;30 mm Hg, administer total daily dose once daily; if supine diastolic pressure is reduced &gt;30 mm Hg, administer in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992014"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage recommendations provided in the manufacturer's labeling; however, the manufacturer suggests that patients with renal failure and/or receiving dialysis may require a dosage reduction.</p></div>
<div class="block doha drugH1Div" id="F50989261"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution and titrate gradually (minoxidil AUC increased 50% and its clearance decreased in mildly cirrhotic patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9840212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9840212'])">Ref</a></span>)).</p></div>
<div class="block doe drugH1Div" id="F8774968"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8774966"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16020" href="/d/html/16020.html" rel="external">see "Minoxidil (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternate agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute severe hypertension with significant but not life-threatening symptoms (eg, severe headache, vomiting but no seizures): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: Initial: 0.1 to 0.2 mg/kg/dose; may repeat every 8 to 12 hours; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011','lexi-content-ref-18839219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011','lexi-content-ref-18839219'])">Ref</a></span>). <b>Note:</b> In situations where rapid blood pressure management required, may increase dose after 6 hours with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic hypertension: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: Recommended for use in refractory hypertension with persistent symptoms or target organ damage despite maximal treatment with a diuretic and 2 antihypertensive agents.</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;12 years: Oral: Initial: 0.2 mg/kg/dose once daily; maximum initial dose: 5 mg/dose; titrate to effect, may increase daily dose by 50% to 100% (eg, 0.1 to 0.2 mg/kg/day) every 3 days; may need to divide doses 1 to 3 times daily; usual daily dose: 0.25 to 1 mg/kg/day in 1 to 3 divided doses; maximum daily dose: 50 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.1','lexi-content-ref-Park.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.1','lexi-content-ref-Park.1','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> In situations where rapid blood pressure management required, may increase dose after 6 hours with careful monitoring.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: Initial: 5 mg once daily; titrate to effect; may increase every 3 days by doubling daily dose (10 mg/day, 20 mg/day, and then 40 mg/day); may need to divide doses 1 to 3 times daily; usual daily dose: 10 to 40 mg/day in 1 to 3 divided doses; maximum daily dose: 100 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.1','lexi-content-ref-Park.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.1','lexi-content-ref-Park.1','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> In situations where rapid blood pressure management required, may increase dose after 6 hours with careful monitoring.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130125"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children and Adolescents: Oral: There are no specific dosage recommendations provided in the manufacturer's labeling; however, the manufacturer suggests that patients with renal failure may require a dosage reduction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Dialyzable. Children and Adolescents: Oral: There are no specific dosage recommendations provided in the manufacturer's labeling; however, the manufacturer suggests that patients receiving dialysis may require a dosage reduction.</p></div>
<div class="block dohp drugH1Div" id="F51130126"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;">Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and titrate gradually (minoxidil AUC increased 50% and its clearance decreased in mildly cirrhotic adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9840212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9840212'])">Ref</a></span>)).</p></div>
<div class="block adr drugH1Div" id="F8774910"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: ECG changes (T-wave changes 60%), edema (reversible, 7% to 10%), pericardial effusion (occasionally with tamponade, 3%), angina pectoris, cardiac failure, pericarditis, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Hypertrichosis (80%), bullous rash (rare), skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Sodium retention, water retention, weight gain</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Decreased hematocrit (transient, hemodilution), decreased red blood cells (transient, hemodilution), hemoglobin (transient, hemodilution), leukopenia (rare), thrombocytopenia (rare)</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Ascites, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Increased blood urea nitrogen (transient), increased serum creatinine (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pulmonary edema (Lee 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Breast tenderness (rare)</p></div>
<div class="block coi drugH1Div" id="F8774907"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to minoxidil or any component of the formulation; pheochromocytoma</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pulmonary hypertension associated with mitral stenosis; severe hepatic impairment</p></div>
<div class="block war drugH1Div" id="F8774908"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid retention: May cause salt and water retention; administer with a diuretic, preferably a loop diuretic (eg, furosemide) to prevent fluid retention and subsequent local and generalized edema. Use with extreme caution in patients with heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pericardial effusion/tamponade: <b>[US Boxed Warning]: May cause pericarditis and pericardial effusion that may progress to tamponade;</b> patients with renal impairment not on dialysis may be at higher risk. Use with caution in patients with heart failure; observe patients closely. If effusion persists, consider discontinuation of minoxidil.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rapid blood pressure control: Rapid control of blood pressure in patients with severe hypertension can lead to syncope, cerebrovascular accidents, MI, and/or ischemia of other special sense organs resulting in decrease or loss of vision or hearing. Patients with compromised circulation or cryoglobulinemia may also suffer ischemic episodes of the affected organs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sinus tachycardia: <b>[US Boxed Warning]: May increase oxygen demand and exacerbate angina pectoris;</b> concomitant use with a beta-blocker (if no contraindication exists) may help reduce the effect. Use with caution in patients with ischemic heart disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute myocardial infarct (MI): Avoid use for a month after acute MI as use may increase oxygen demand due to reflex tachycardia. Use with extreme caution; ensure patient is receiving a beta blocker prior to initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Compared to placebo minoxidil increased the frequency of clinical events, including increased need for diuretics, angina, ventricular arrhythmias, worsening heart failure and death (Franciosa 1984). In a scientific statement from the American Heart Association, minoxidil has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with significant renal impairment; renal failure and dialysis patients may require a smaller dose. Monitor closely to prevent exacerbation of renal failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; initiate at the low end of the dosage range and monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[US Boxed Warning]: Maximum therapeutic doses of a diuretic and two other antihypertensives should be used before this drug is ever added. Should be given with a diuretic to minimize fluid gain and a beta-blocker (if no contraindications) to prevent tachycardia and increased myocardial workload. Patients with malignant hypertension and those already receiving guanethidine should be hospitalized with close medical supervision to ensure blood pressure is reducing and to prevent too rapid of a reduction in blood pressure.</b></p></div>
<div class="block foc drugH1Div" id="F8774977"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F8774869"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8774979"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Minoxidil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.59 - $0.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.29 - $1.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869250"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loniten: 2.5 mg, 10 mg</p></div>
<div class="block admp drugH1Div" id="F52614376"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food</p></div>
<div class="block use drugH1Div" id="F8774881"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypertension:</b> Management of hypertension that is symptomatic or associated with target organ damage, and is not manageable with maximum therapeutic doses of a diuretic plus 2 other antihypertensives. Use in milder degrees of hypertension is not recommended because the benefit-risk ratio in such patients has not been defined.<b> Note:</b>
<b>Not</b> recommended for the initial treatment of hypertension (ACC/AHA [Whelton 2018]).</p></div>
<div class="block mst drugH1Div" id="F8774841"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Loniten [CAN] may be confused with Lipitor</p>
<p style="text-indent:-2em;margin-left:4em;">Minoxidil may be confused with metOLazone, midodrine, Minipress, Minocin, Monopril, Minoxidin (dietary supplement), Noxafil</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Noxidil [Thailand] may be confused with Noxafil brand name for posaconazole [US and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299718"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8774914"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Minoxidil (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Minoxidil (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Minoxidil (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Minoxidil (Systemic).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F8774883"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal studies. Neonatal hypertrichosis has been reported following exposure to minoxidil during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F8774906"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Excretion in breast milk has been reported in one case report of a woman receiving 10 mg/day orally. Due to the potential for adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F8774970"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure; heart rate; signs/symptoms of pericardial effusion or cardiac tamponade; signs/symptoms of angina; fluid and electrolyte balance and body weight. Any tests that are abnormal at the time of initiation (including, renal function tests, ECG, echocardiogram, chest x-ray) should be repeated initially every 1 to 3 months then every 6 to 12 months once stable.</p></div>
<div class="block pha drugH1Div" id="F8774941"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Produces vasodilation by directly relaxing arteriolar smooth muscle, with little effect on veins; effects may be mediated by cyclic AMP; stimulation of hair growth is secondary to vasodilation, increased cutaneous blood flow and stimulation of resting hair follicles</p></div>
<div class="block phk drugH1Div" id="F8774942"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Hypotensive: ~30 minutes</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Up to 2 to 5 days</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: None</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: ~90%, primarily via glucuronidation</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 90%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 3.5 to 4.2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (12% as unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12707702"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lonolox</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lonnoten</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Minox | Minoxiten | Vaxdil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Loniten | Lonolox | Lonoten</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Minoxiten</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Minoxiten</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lonnoten | Minona</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lonoten</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Loniten | Lonnoten | Oxofenil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dilminox | Dutamax m | Lonit | Staha</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bimo | Dhnp minoxidil | Dongkwang Minoxidil | Highnoxil | Hyundai minoxidil | Introminoxidil | Loniten | Momosidil | Plexidil | Uni minoxidil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lonitab | Loniten | Lonolox | Minoxiheart</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lonnoten</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hirsutin | Loniten</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lonnoten</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Loniten | Lonnoten | Lonolox | Minoxidil sun pharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Loniten | Lonolox | Lonoten</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Loniten | Minoxidil for men</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Loniten | Loxidil | Manoxidil | Minoxy | Modil | Mpb | Noxidil | Pipminox | Sm 2 | Sm-1</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Loniten | Minoten</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Guayaten</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Loniten</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9840212">
<a name="9840212"></a>Adams MH, Poynor WJ, Garnett WR, et al. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers. <i>Biopharm Drug Dispos</i>. 1998;19(8):501-515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/9840212/pubmed" id="9840212" target="_blank">9840212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brook.2022">
<a name="Brook.2022"></a>Brook RD, Townsend RR. Treatment of resistant hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29192011">
<a name="29192011"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904. doi:10.1542/peds.2017-3035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/29192011/pubmed" id="29192011" target="_blank">29192011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18839219">
<a name="18839219"></a>Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. <i>Pediatr Nephrol</i>. 2009;24(6):1101-1112. doi:10.1007/s00467-008-1000-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/18839219/pubmed" id="18839219" target="_blank">18839219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6373050">
<a name="6373050"></a>Franciosa JA, Jordan RA, Wilen MM, et al, “Minoxidil in Patients With Chronic Left Heart Failure: Contrasting Hemodynamic and Clinical Effects in a Controlled Trial,” <i>Circulation</i>, 1984, 70(1):63-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/6373050/pubmed" id="6373050" target="_blank">6373050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lee.1">
<a name="Lee.1"></a>Lee C, Chen K, Kao H. Minoxidil-related renal function deterioration and pulmonary edema: A case report and literature review. <i>Acta Nephrologica</i>. 2011; 25(1):33-36. Available at http://www.tsn.org.tw/tsnFile/journal/catalog/D8CDBE5E9A81035C/33-36.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Loniten.1">
<a name="Loniten.1"></a>Loniten (minoxidil) [prescribing information]. New York, NY: Pfizer, Inc; January 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Loniten.2">
<a name="Loniten.2"></a>Loniten (minoxidil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; November 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minoxidil.1">
<a name="Minoxidil.1"></a>Minoxidil [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical Companies, Inc; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minoxidil.2">
<a name="Minoxidil.2"></a>Minoxidil [prescribing information]. Pulaski, TN: AvKARE Inc; July 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Clinical Practice Guidelines, 2011. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Date accessed: June 11, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <a href="http://www.nhlbi.nih.gov/files/docs/resources/heart/hbp_ped.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/resources/heart/hbp_ped.pdf</a>. Updated May 2005. Accessed February 2, 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park MK, Salamat M. <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021:chap. 28, appendix E.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):e13‐e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minoxidil-systemic-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9598 Version 234.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
